

Resource Summary Report

Generated by [RRID](#) on Aug 8, 2026

SHP-2 (D50F2) XP(tm) Rabbit mAb

RRID:AB_2174959

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3397, RRID:AB_2174959

Antibody Information

URL: http://antibodyregistry.org/AB_2174959

Proper Citation: Cell Signaling Technology Cat# 3397, RRID:AB_2174959

Target Antigen: Ptpn11

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P. Consolidation on 10/2018: AB_10434986, AB_10860425, AB_2174959.

Antibody Name: SHP-2 (D50F2) XP(tm) Rabbit mAb

Description: This monoclonal targets Ptpn11

Target Organism: rat, mouse, human

Antibody ID: AB_2174959

Vendor: Cell Signaling Technology

Catalog Number: 3397

Record Creation Time: 20250820T045910+0000

Record Last Update: 20250820T202822+0000

Ratings and Alerts

No rating or validation information has been found for SHP-2 (D50F2) XP(tm) Rabbit mAb.

No alerts have been found for SHP-2 (D50F2) XP(tm) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Entrialgo-Cadierno R, et al. (2026) Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma. *Cancer cell*, 44(6), 1218.

Ge X, et al. (2026) PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition. *Cancer research*, 86(15), 3819.

Kremmyda P, et al. (2026) SHP2 regulates VEGFR2 Y1175/PLC γ signaling to impair tumor endothelial barrier stability. *iScience*, 29(2), 114784.

Karunaraj P, et al. (2026) A hotspot phosphorylation site on SHP2 drives oncoprotein activation and drug resistance. *Nature communications*, 17(1).

Postlmayr A, et al. (2026) Functionally distinct ALK and ROS1 fusions detected in infant-type hemispheric gliomas converge on STAT3 and SHP2 activation. *Cell reports*, 45(3), 117046.

Karunaraj P, et al. (2025) A Hotspot Phosphorylation Site on SHP2 Drives Oncoprotein Activation and Drug Resistance. *Research square*.

Karunaraj P, et al. (2025) A Hotspot Phosphorylation Site on SHP2 Drives Oncoprotein Activation and Drug Resistance. *bioRxiv : the preprint server for biology*.

Xiao L, et al. (2024) m6A mRNA methylation in brown fat regulates systemic insulin sensitivity via an inter-organ prostaglandin signaling axis independent of UCP1. *Cell metabolism*, 36(10), 2207.

Shi M, et al. (2024) Genetic and microenvironmental evolution of colorectal liver metastases under chemotherapy. *Cell reports. Medicine*, 5(12), 101838.

Wu Q, et al. (2024) Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(1), 198.

Andreska T, et al. (2023) DRD1 signaling modulates TrkB turnover and BDNF sensitivity in direct pathway striatal medium spiny neurons. *Cell reports*, 42(6), 112575.

Chen L, et al. (2023) SHP2 participates in decidualization by activating ERK to maintain normal nuclear localization of progesterone receptor. *Reproduction (Cambridge, England)*, 166(1), 37.

Kaehler M, et al. (2023) Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models. *Frontiers in oncology*, 13, 1200897.

Cai J, et al. (2022) High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition. *Cell reports*, 40(4), 111095.

Wei B, et al. (2021) SHP2-Mediated Inhibition of DNA Repair Contributes to cGAS-STING Activation and Chemotherapeutic Sensitivity in Colon Cancer. *Cancer research*, 81(12), 3215.

Yao F, et al. (2021) A targetable LIFR-NF- κ B-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. *Nature communications*, 12(1), 7333.

Vemulapalli V, et al. (2021) Time-resolved phosphoproteomics reveals scaffolding and catalysis-responsive patterns of SHP2-dependent signaling. *eLife*, 10.

Paavola KJ, et al. (2021) The Fibronectin-ILT3 Interaction Functions as a Stromal Checkpoint that Suppresses Myeloid Cells. *Cancer immunology research*, 9(11), 1283.

Tulpule A, et al. (2021) Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules. *Cell*, 184(10), 2649.

Zhu G, et al. (2020) Phase Separation of Disease-Associated SHP2 Mutants Underlies MAPK Hyperactivation. *Cell*, 183(2), 490.